Ed Arce
Stock Analyst at WestPark Capital
(4.20)
# 477
Out of 5,008 analysts
471
Total ratings
47.31%
Success rate
16.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $24 → $28 | $11.08 | +152.71% | 13 | Sep 30, 2025 | |
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $25.50 | +17.65% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $12 | $1.06 | +1,032.08% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $75 | $4.63 | +1,519.87% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $20.47 | +193.11% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $2.95 | +154.24% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $5.52 | +135.51% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $4.77 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $1.26 | +376.19% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $9.75 | +617.95% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $23.86 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $240 | $4.29 | +5,494.41% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.48 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $7.34 | +335.97% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $35 | $102.17 | -65.74% | 22 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $75 | $46.00 | +63.04% | 25 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $29 → $21 | $14.83 | +41.60% | 22 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $73.74 | -2.36% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $436.28 | -7.17% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $5.17 | +6.38% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $29.74 | +219.44% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $3.96 | +228.28% | 18 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $4.29 | +16.55% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $32.21 | +49.02% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $7.99 | -6.13% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.76 | +557.89% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $11.71 | +11.02% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.70 | - | 8 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $30.80 | -18.83% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.58 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $22.29 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $31.54 | -77.80% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $33.39 | -37.11% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.97 | - | 2 | Feb 15, 2017 |
Enanta Pharmaceuticals
Sep 30, 2025
Maintains: Buy
Price Target: $24 → $28
Current: $11.08
Upside: +152.71%
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $25.50
Upside: +17.65%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $12
Current: $1.06
Upside: +1,032.08%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $75
Current: $4.63
Upside: +1,519.87%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $20.47
Upside: +193.11%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $2.95
Upside: +154.24%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $5.52
Upside: +135.51%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $4.77
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $1.26
Upside: +376.19%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $9.75
Upside: +617.95%
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $23.86
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $240
Current: $4.29
Upside: +5,494.41%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.48
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $7.34
Upside: +335.97%
Mar 10, 2025
Maintains: Buy
Price Target: $24 → $35
Current: $102.17
Upside: -65.74%
Mar 3, 2025
Maintains: Buy
Price Target: $72 → $75
Current: $46.00
Upside: +63.04%
Feb 28, 2025
Reiterates: Buy
Price Target: $29 → $21
Current: $14.83
Upside: +41.60%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $73.74
Upside: -2.36%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $436.28
Upside: -7.17%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $5.17
Upside: +6.38%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $29.74
Upside: +219.44%
Feb 7, 2025
Reiterates: Buy
Price Target: $13
Current: $3.96
Upside: +228.28%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $4.29
Upside: +16.55%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $32.21
Upside: +49.02%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $7.99
Upside: -6.13%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $0.76
Upside: +557.89%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $11.71
Upside: +11.02%
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.70
Upside: -
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $30.80
Upside: -18.83%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.58
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $22.29
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $31.54
Upside: -77.80%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $33.39
Upside: -37.11%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $2.97
Upside: -